Taysha Gene Therapies (TSHA) to Release Quarterly Earnings on Wednesday

Taysha Gene Therapies (NASDAQ:TSHA) is expected to post its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Taysha Gene Therapies to post earnings of ($0.11) per share and revenue of $1.8890 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 5, 2026 at 9:30 AM ET.

Taysha Gene Therapies Stock Performance

NASDAQ:TSHA opened at $4.70 on Monday. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of -14.24 and a beta of 1.01. The firm’s fifty day moving average price is $5.01 and its 200 day moving average price is $4.33. Taysha Gene Therapies has a 1-year low of $1.05 and a 1-year high of $6.02.

Analyst Ratings Changes

Several research analysts recently issued reports on TSHA shares. Citizens Jmp set a $8.00 price target on shares of Taysha Gene Therapies in a report on Wednesday, November 5th. The Goldman Sachs Group set a $11.00 target price on Taysha Gene Therapies in a research report on Thursday, December 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Monday, December 29th. Chardan Capital restated a “buy” rating and issued a $12.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. Finally, Wells Fargo & Company increased their price objective on Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.91.

Insiders Place Their Bets

In other Taysha Gene Therapies news, CEO Sean P. Nolan sold 136,789 shares of the company’s stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $4.75, for a total value of $649,747.75. Following the sale, the chief executive officer owned 2,949,569 shares of the company’s stock, valued at $14,010,452.75. This represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Kamran Alam sold 78,968 shares of the stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $4.75, for a total transaction of $375,098.00. Following the completion of the sale, the chief financial officer owned 1,467,635 shares in the company, valued at $6,971,266.25. This represents a 5.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 968,795 shares of company stock worth $4,518,093. Insiders own 3.78% of the company’s stock.

Institutional Trading of Taysha Gene Therapies

A number of large investors have recently made changes to their positions in TSHA. Marex Group plc acquired a new position in Taysha Gene Therapies in the 2nd quarter valued at about $29,000. E Fund Management Co. Ltd. purchased a new position in shares of Taysha Gene Therapies during the second quarter valued at approximately $31,000. Tower Research Capital LLC TRC lifted its stake in shares of Taysha Gene Therapies by 156.5% during the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock valued at $41,000 after buying an additional 10,742 shares during the period. BNP Paribas Financial Markets boosted its position in Taysha Gene Therapies by 51.9% during the second quarter. BNP Paribas Financial Markets now owns 18,591 shares of the company’s stock worth $43,000 after acquiring an additional 6,350 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its stake in Taysha Gene Therapies by 143.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock worth $43,000 after acquiring an additional 4,607 shares during the period. Institutional investors and hedge funds own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.